key: cord-0985253-r8per91p
authors: Farouk, Abd-ElAziem; Hassan Baig, Mohammad; Imran Khan, Mohd; Tae Hwan, Park; Alotaibi, Saqer S.; Dong, Jae-Jun
title: Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A Viroinformatics study
date: 2021-02-26
journal: Saudi J Biol Sci
DOI: 10.1016/j.sjbs.2021.02.066
sha: 03c2e3fe6f0f99a4055fda864d8940cb0f2d9b4b
doc_id: 985253
cord_uid: r8per91p

SARS-CoV-2, previously named 2019 novel coronavirus (2019-nCoV), has been associated with the global pandemic of acute respiratory distress syndrome. First reported in December 2019 in the Wuhan province of China, this new RNA virus has several folds higher transmission among humans than its other family member (SARS-CoV and MERS-CoV). The SARS-CoV-2 spike receptor-binding domain (RBD) is the region mediating the binding of the virus to host cells via Angiotensin-converting enzyme 2 (ACE2), a critical step of viral. Here in this study, we have utilized in silico approach for the virtual screening of antiviral library extracted from the Asinex database against the Receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike glycoprotein. Further, the molecules were ranked based on their binding affinity against RBD, and the top 15 molecules were selected. The affinity of these selected molecules to interrupt the ACE2-Spike interaction was also studied. It was found that the chosen molecules were demonstrating excellent binding affinity against spike protein, and these molecules were also very effectively interrupting the ACE2-RBD interaction. Furthermore, molecular dynamics (MD) simulation studies were utilized to investigate the top 3 selected molecules' stability in the ACE2-RBD complexes. This is the first study where molecules' inhibitory potential against the Receptor binding domain (RBD) of the S1 subunit of the SARS-CoV-2 spike glycoprotein and their inhibitory potential against the ACE2-Spike has been studied. We believe that these compounds can be further tested as a potential therapeutic option against COVID-19.

novel coronavirus (2019-nCoV), has been associated with the global pandemic of acute respiratory distress syndrome [7] . First reported in December 2019 in the Wuhan province of China this new RNA virus has several folds higher transmission among humans than its other family members (SARS-CoV and MERS-CoV) [8] [9] [10] . Declared as a global pandemic by WHO, the disease caused by this virus (SARS-CoV-2) was termed as Coronavirus Disease 2019 . The person infected with SARS-CoV-2 is shown to be showing a wide range of symptoms, leading to respiratory, gastrointestinal diseases, and even death [11, 12] . As of 27 th October 2020, a total of 43.4 million confirmed cases of COVID-19 were reported worldwide, which includes 1.16 million deaths. This major suffering of the worldwide population due to SARS-COV-2 mediated disease has raised the alarm for the instant call for antiviral drugs for treatment/prevention against Belonging to the Coronaviridae family of order Nidovirales, CoV has been classified into different genera which include α-, β-, γ-, and δ-coronaviruses [13, 14] . Among these different genera, α-β-and δ-CoVs infects the mammals, while the γ-coronaviruses mainly infect avian species [15, 16] . The δ-coronaviruses are also reported to be infecting aves as well [17] .

Coronaviruses are comprised of the largest RNA viral genome (26 -32 kb) [18, 19] . The genomes of Coronaviruses share a significant similarity; for instance, the SARS-CoV-2 genome share ~82% similarity with the SARS-CoV and MERS-CoV. This high level of sequence similarity leads to these coronaviruses' common pathogenesis mechanism, and thus therapeutic targeting [17, 19] . The viral genome of SAR-CoV-2 encodes for several structural as well as non-structural proteins. There are four structural proteins in SARS-CoV-2, that include envelope (E), membrane (M), spike (S), and nucleocapsid (N) proteins, which are playing a prominent role in the viral assembly [20, 21] [ Figure 1 ]. These structural proteins are found to be sharing high sequence similarity with their SARS-CoV, and MERS-CoV counterparts. Among all the structural proteins, the main role is played by the S protein, which is responsible for the cell membrane fusion, viral attachment, and viral entry. These features of S protein make it an important therapeutic target [22] [23] [24] . The S1 subunit of S protein (RBD region) binds to the host receptor, Angiotensin-converting enzyme 2 (ACE2), while the S2 subunit mediates the viral cell membrane fusion [24, 25] [ Figure 1 ]. Studies have found that, like SARS-CoV, SARS-CoV-2 also utilizes the same host viral entry mechanism where its homotrimeric spike (S) glycoprotein binds to the host ACE2 (its functional host receptor) [26] [27] [28] . The Receptor binding domain (RBD) of the S protein is the region involved in the most critical step of viral entry within the target host cell i.e., it is the region that mediates the binding of the virus to host cells [28, 29] .

Here in this study, we have utilized in silico approach for the virtual screening of Asinex antiviral compound library against the RBD of the S1 subunit of the SARS-CoV-2 spike glycoprotein.

Further, the molecules were ranked based on their binding affinity against RBD, and the top 15 molecules were selected. The affinity of these selected molecules to disrupt the ACE2-RBD interaction was also studied. Our study shows that the selected molecules demonstrate very good binding affinity against spike protein and effectively disrupt the ACE2-RBD interaction.

Furthermore, molecular dynamics (MD) simulation studies were utilized to study the top 3 selected compounds' stability in the ACE2-RBD complexes. This is the first study, where the inhibitory potential of molecules against the RBD of the S1 subunit of the SARS-CoV-2 spike glycoprotein and their inhibitory potential against the ACE2-RBD has been studied. We believe that these compounds may be a potential therapeutic option for the treatment of COVID-19.

The 3D structure of Spike protein (RBD) in complex with the human ACE-2 was retrieved from the RCSB protein data bank (pdb id: 6m0j) [30, 31] . Further both the RBD and ACE-2 were separated and the HEATM and other solvent molecules were removed. The separated structure of Spike protein (RBD) was considered for the virtual screening of antiviral compounds. The antiviral library comprising of 6827 antiviral compounds was downloaded from the Asinex database. Further, the library was screened against the SARS-CoV-2 spike protein. The virtual screening was performed using CCDC Gold [32] , and the molecules were ranked based on their PLP Fitness score. The top selected molecules in complex with the SARS-CoV-2 spike protein were considered for further study.

The spike receptor-binding domain (Chain E) and ACE-2 (Chain A) were separated from the 3D complexed structure of ACE-2-RBD (pdb id: 6m0j). The separated structures of Spike protein (RBD) and human ACE-2 were redocked using Patchdock [33] . The generated results were further refined for 1000 steps using firedock [34] . The top-scoring complex was selected based on the global energy score and was compared to its crystal counterpart. The global energy of this complex was taken as a reference for further study.

Further, the protein-protein interaction study was performed using the same protocol, but this time the top-scoring molecules in complex with the Spike protein (RBD) were docked against the human ACE-2. The global score of all the complexes was compared with the reference score.

The structure of Spike protein (RBD) in complex with the human ACE-2 in the presence of the top selected compound was further subjected to MD simulation studies using DESMOND [35] .

Here in this study, the OPLS3 force field was used to perform the MD simulation studies [36] .

The first step was building the simulation systems using the OPLS3 force field for proteins, followed by their SPC solvation in the Orthorhombic box. Further, the counter ions were added for neutralizing the systems. A series of energy minimization steps were performed to relax the system. MD was performed for 10 ns using NPT ensemble. The backbone root mean square deviation (RMSD) plot for proteins, and the ligand was calculated using the initial starting structure as a reference frame. Likewise, the root mean square fluctuation (RMSF) was also calculated.

The present study was focused on finding the potent inhibitor candidates against the RBD of the S1 subunit of the SARS-CoV-2 spike glycoprotein. We further assessed the potential of these selected inhibitor candidates to disrupt the binding of RBD to the ACE2 receptor ( Table 2 ). The flow chart of the complete work is shown in Figure 2 . The library of 6827 molecules was screened against the S-protein (RBD) of SARS-CoV-2. The molecules were evaluated based on their PLP fitness score. The top 15 effective molecules with a high binding affinity (PLP Fitness score) were selected (Table 1 ). The selected most effective molecules were further evaluated for their affinity to disrupt the interaction of SARS-CoV-2 spike protein (RBD) with the human host receptor (ACE-2). These 15 compounds with high binding affinity against RBD are enlisted in Table 1 . Further, the complex of top-scoring 15 molecules with spike protein was prepared.

These complexes were further subjected to PPI study against ACE2. It was found that the presence of the above-mentioned compounds affects the binding of the RBD to its natural interacting partner, the ACE2 receptor. The selected top fifteen hits were ranked based on their affinity to interrupt the ACE2-RBD interaction (global energy). Compound 148, 6612, and 107

were the most potent inhibitors that disrupted ACE2-RBD interaction. These compounds (Figure 4d ).

The COVID-19 outbreak, caused by the SARS-CoV-2, has strongly affected all walks of life and has become a severe public health concern [37] [38] [39] . At present, there is no available drug or antiviral for the treatment against SARS-CoV-2, and the development of new drug molecules will take time [40] . Several antivirals have been reported to inhibit the pathogenesis of chikungunya, dengue virus, or other RNA viruses by either blocking the viral entry or inhibiting their replication at different stages [41, 42] . The S protein of SARS-CoV-2 is composed of 1273 amino acids. The initial 12 residues at N-terminus form the signal peptides while the rest of the mature part is proteolytically processed into two subunits (S1 & S2) [43, 44] . Subunit S1 comprises amino acids from 14 to 685, and residues between 686 to 1273 encodes for subunit S2 [45, 46] . The S1 subunit of the spike glycoprotein is responsible for the host cell receptor binding (ACE-2), while the S2 subunit is responsible for the fusion of the virus to the host cell's membrane [45, 47] [ Figure 1 ]. It has been found that the RBD (amino acids 319-541) of the S1 subunit of SARS-CoV-2 binds to the outer surface of ACE2 (claw-like structure) of the host [24, 45, [47] [48] [49] [50] . ACE2 is the primary host target of SARS-CoV-2 spike protein [48] . It is located on the cell's outer surface and has been widely reported to be the primary host cell target, thereby playing a prominent role in the viral entry [49, [51] [52] [53] [ Figure 1 ]. Since this interaction is an essential step facilitating the entry of SARS-CoV-2 within the host cell, the compounds targeting S-RBD-ACE2 interface and thereby blocking this protein-protein interaction could be a potential therapeutic candidate against COVID-19, inhibiting the viral entry into host cell [54] . The crystal structure of SARS-CoV-2 spike RBD bound with ACE2 was considered for the in silico studies [31] . We have utilized the in silico virtual screening approach to screen the antiviral library (Asinex) against the RBD of the SARS-CoV-2 spike glycoprotein. We determined the binding affinity and evaluated the binding conformation of molecules within the RBD's active site. The study seeks to identify small molecules carrying inhibitory potential against the spike protein (RBD), and they must be capable of disrupting the binding of RBD-ACE-2 as well. The PPI study revealed that the active site residues of SARS-CoV-2 spike protein (RBD) viz. Tyrosine Table 3 ]. The role of these active site residues of RBD has been previously well defined [31, 55, 56] . These residues were also involved in accommodating the small molecules within the active site of spike protein (RBD) as well. It was observed that the binding of all the compounds within the active site of RBD was dominated by hydrophobic interaction, and hydrogen bond interactions involving R403, Y453, G496, Q498, G502, and Y505 residues [ Table 1 and 3]. Our findings reveal high flexibility in the residues remote to the RBD interface of ACE2, and the finding is in accordance with other earlier reports [57] . The high degree of amino acid fluctuation was also noticed in the RBD and the fluctuation was most in the compound 107 bound structure as compare to structures containing compounds 6612 and 148. The analysis provides us with the idea that the RBD of SARS-CoV-2 spike protein remained bound to human ACE2, in the presence of compound 6612 and compound 148, compared to compound 107 [ Figure 4d ]. It was also observed that despite the substantial conformational changes within the ACE2 and RBD, the complexes were tightly bound. These observations also imply that the region at the binding interface in the ACE2-RBD complex was stable throughout the simulation compared to the other areas. The ACE2

interfacing residues exhibited minimum conformational changes. This supports that the complex was most stable in the presence of compound 6612, followed by compound 147, while it was unstable in the presence of compound 107. A high degree of fluctuation was observed for the residues 365-385, 415-435, and the loop region residues (477-485) of RBD (Figure 4d) . We observed the prominent involvement of the residues 477-485 of the loop region at the interface binding site, and our findings are in the right perspective as has been reported earlier for the involvement of the residues of the loop region binding to the ACE2 receptor [57, 58] .

The Asinex antiviral library's virtual screening against the receptor binding domain of SARS-CoV-2 spike protein provides us a list of several active compounds, with high binding affinity against the receptor binding domain. The further assessment of these compounds' potential to inhibit the ACE2-RBD interaction provides an additional valuable feature to them. Compound 107, 148, and 6612 were found to be the most active compounds, capable of binding to RBD and interrupting the ACE2-RBD interaction as well. MD simulation studies showed that in the presence of compound 6612, the ACE2-RBD complex was most stable, followed by 107 and 148. The importance of essential residues has also been explored in this study. It was noticed that the conformational changes were majorly in the residues far away (remote) from the interface region of ACE2. This information provided will be of great help in using these compounds as possible drug candidates against COVID19 and may also help for future drug discovery.

All the authors declare no conflict of interest. 

From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses

Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses

Coronaviruses: important emerging human pathogens

The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat

Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea

A new threat from an old enemy: Reemergence of coronavirus (Review)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan

Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China

Coronavirus diversity, phylogeny and interspecies jumping

Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus

Identification of a novel coronavirus from a beluga whale by using a panviral microarray

Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach

Coronavirus disease 2019 (COVID-19): current status and future perspectives

Comparative genome analysis of novel coronavirus (SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Vaccines for the prevention against the threat of MERS-CoV

The spike protein of SARS-CoV--a target for vaccine and therapeutic development

MERS-CoV spike protein: a key target for antivirals

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism

RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Development and validation of a genetic algorithm for flexible docking

PatchDock and SymmDock: servers for rigid and symmetric docking

FireDock: a web server for fast interaction refinement in molecular docking

Scalable algorithms for molecular dynamics simulations on commodity clusters, SC'06: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing

Development and Testing of the OPLS-AA/M Force Field for RNA

Quarantine during COVID-19 outbreak: Changes in diet and physical activity increase the risk of cardiovascular disease

An interactive web-based dashboard to track COVID-19 in real time

Beware of the second wave of COVID-19

Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach

Inhibition of Chikungunya virus by an adenosine analog targeting the SAM-dependent nsP1 methyltransferase

Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease

Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2

Structure analysis of the receptor binding of 2019-nCoV

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment

Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis

Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms

Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms

Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis

Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2

Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein

The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor